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Cognitive-Educational Treatment of Fibromyalgia: 
A Randomized Clinical Trial. II. Economic Evaluation
MARIËLLE E.J.B. GOOSSENS, MAUREEN P.M.H. RUTTEN-van MOLKEN, REINER M. LEIDL, 
STEFAN G.P.M. BOS, JOHAN W.S. VLAEYEN, NICOLE J.G. TEEKEN-GRUBEN
ABSTRACT. Objective. In this 3 year randomized clinical trial the cost effectiveness of a 6 week educational/cog­
nitive intervention (ECO) is compared with an educational discussion intervention (EDI) and a wait­
ing list condition (WLC).
Methods. A total of 13 1 patients with fibromyalgia were randomly allocated to the ECO, EDI, or 
WLC intervention. The ECO and EDI groups were followed for 12 months, whereas the WLC group 
was followed for 6 weeks. Direct health care and nonhealth care costs, and the indirect costs asso­
ciated with lost production due to illness, were calculated. The effects were measured in terms of 
utilities, using rating scale and standard gamble methods.
Results. Treatment costs were estimated to be US $980 per patient for both ECO and EDI, The total 
direct health care costs of  ECO treatment were US $1623 higher than those for EDI. This difference 
was significant. Indirect costs for the 2 groups were not significantly different. At 6 weeks there was 
a significant difference in rating scale utilities between the 3 groups, caused by a significantly 
greater improvement in the EDI group compared to the WLC group. However, no significant dif­
ferences in either rating scale or standard gamble utilities were found between the ECO and EDI 
groups immediately after treatment, or at the 6 or 12  month followups.
Conclusion. The economic evaluation showed that the addition of a cognitive component to the edu­
cational intervention led to significantly higher health care costs and no additional improvement in 
quality of life compared to the educational intervention alone. This conclusion is robust through a 
range of plausible values used in a sensitivity analysis. (J Rheumatol 7995/23:1246-54)
Key Indexing Terms:
FIBROMYALGIA COSTS COGNITIVE-BEHAVIORAL TREATMENT
ECONOMIC EVAULATION UTILITIES QALY
Fibromyalgia (FM) is a chronic pain syndrome associated 
with symptoms of stiffness and fatigue. It has a significant 
effect on quality of life1. Patients frequently have pain, 
depression, anxiety, decreased participation and pleasure in 
leisure activities, impaired function in daily life or at work, 
and increased dependence on family and friends2“4. 
Although there are no detailed cost of illness studies for FM, 
it is associated with extensive health care utilization due to 
the absence of a clear etiology or effective therapies. A study 
of the health service utilization of 81 patients with FM2 
showed that their use of outpatient medical services was 
higher than outpatient services use of both the control sub­
jects and the national averages. However, the health care uti-
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lization was similar to that of the patients with other chron­
ic pain disorders such as osteoarthritis and low back pain. 
This study also found very high hospitalization rates before 
FM was diagnosed. Several studies have shown that job lim­
itations are associated with FM1,2,5,6. A study of disability 
claims paid by a large Canadian insurance company shows 
that over 50% of patients with FM who receive such a bene­
fit are disabled for more than 2 years5. These longterm dis­
ability payments and compensation arising from litigation 
reflect the considerable loss of potentially productive years 
from FM. However, these studies all report on work disabil­
ity, which may be an underestimate of the total indirect 
costs, since in most studies more than 85% of the patients 
are women without a paid job.
Despite the considerable burden and costs associated 
with FM and the increasing need to use resources efficiently, 
only one economic evaluation of treatments for FM was 
found. This study7 investigated the treatment of patients 
with FM with Lyme disease using intravenous antibiotics. 
The drug was directed at the Lyme disease. Therapy costs, 
including the costs of treating side effects, were more than 
US $80,000 for every case of Lyme disease that was treated 
effectively. The cost calculations in this study were limited 
to the costs of health care utilization, which is not sufficient 
to economically evaluate a chronic disease. In a chronic ill­
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ness such as FM, the costs borne by patients and their fam­
ilies and the costs of lost productivity are likely to be sub­
stantial and should not be excluded. Full economic evalua­
tions compare alternative treatments with respect to all rele­
vant costs and effects. Since there are not sufficient 
resources to support every new intervention, the results of 
such full economic evaluations can be used to inform deci­
sion makers about the most efficient use of the scarce 
resources, so that the total health gains from the use of these 
resources can be maximized.
The main question we address is whether a combined 
educational/cognitive therapy is effective, and cost effective 
compared to educational therapy alone. To assess the short 
term effect of both therapies, a control group of patients on 
the waiting list was also followed. To our knowledge this is 
the first full economic evaluation of a treatment modality for 
FM. The societal perspective has been adopted in this study 
because of the wide array of social and economic conse­
quences of FM, as described.
MATERIALS AND METHODS
Study design. In a 3 year randomized controlled clinical trial, 131 patients 
aged 18-65 who met the American College of Rheumalology criteria for 
FM were randomly assigned to an educational cognitive group (ECO, 49 
patients), an educational discussion group (EDI, 39 patients), and a waiting 
list condition (WCL, 43 patients). The ECO and EDI treatments were struc­
tured so that groups of 6 patients participated in a 6 week program of 12 
half-day treatment sessions at the outpatient clinic of a rehabilitation cen­
ter. The group discussion component of the EDI program was intended as 
an attention control for possible aspecific effects of the cognitive treatment. 
Details regarding the content of the treatment programs are published13.
All patients were seen at the outpatient clinic of the rehabilitation cen­
ter 2 weeks before the start of the treatment (PRE1 ), at the start of treatment 
(PRE2), after completion of the 6 week (POST) treatment program, and 6 
(FU1 ) and 12 months (FU2) after termination of treatment. Patients in the 
WLC group were followed for 6 weeks after randomization. This group
«
was included only to measure the short term effects of ECO and EDI treat­
ments.
Clinical effects were expressed in terms of 5 primary measures (pain 
control, pain coping, knowledge, tension, and relaxation), 4 secondary 
measures (catastrophizing, pain intensity, pain behavior, activities), and 3 
affective measures (fear, depression, and obsessive-compulsiveness), as 
described13. We focus here on the outcomes, in terms of costs and utilities 
(where utilities are values assigned to the patient’s quality of life). The eco­
nomic evaluation specifically addresses the question whether the addition 
of cognitive therapy to educational therapy is cost effective compared to 
educational therapy alone.
Costs. To evaluate the economic consequences, the direct health care and 
nonhealth care costs were considered, as well as the indirect costs. The 
direct health care costs included the costs of the ECO and EDI treatment 
programs and of all other pain related health care utilization, which 
includes GP contacts, outpatient specialist contacts, physiotherapy, alterna­
tive health care, hospitalizations, home help, prescribed medications, and 
over the counter medications. Direct nonhealth care costs include costs of 
paid and unpaid help, transportation costs, out of pocket expenses for pain 
related activities and purchases. Indirect costs refer to the value of the pro­
duction lost due to illness related absence from work or days lost from 
housekeeping. The costs in 1993 Dutch guilders have been converted into 
US dollars ($) at the 1993 Purchasing Power Parities rate* of 2.134:1 
(OECD Health Data File, 1995). Table I provides an overview of the unit 
prices of important cost components.
Program costs. The calculation of total costs per patient of the ECO and 
EDI programs was based on the volumes in the program protocols, the time 
schedules of therapists, and detailed cost accounting studies in the rehabil­
itation center using the direct allocation method to allocate service depart­
ment costs to production departments.
Direct health care costs. Data on pain related health care utilization was 
obtained from patients using a weekly cost diary that was specifically 
developed for this study. It covered visits to the GP, outpatient specialist, 
and physiotherapist, hospitalizations, alternative health care, over the 
counter medications, and prescribed medications. The prescribed medica­
tion was later subdivided into antirheumatics, analgesics, sleep inducers 
and tranquilizers, antipsychotics, and antidepressants. Patients were asked 
to complete this diary for the entire study period. It was left to the judgment 
of the patient whether particular items of health care utilization were relat­
ed to their FM.
*Purchasing Power Parities (PPP) are rates of currency conversion that 
equalize the purchasing power of different currencies. The PPP conversion 
rate eliminates the differences in price levels between countries.
7able I. Unit prices used in calculations of direct health care and nonhealth care costs (US dollars).
Unit Price/Contact (US$) Unit Price/Contact (US$)
General practitioner 28.68 Alternative health care
Outpatient specialist Homeopath 90.00
Rheumatologist 32.06 Acupuncturist 180.00
Neurologist 37,07 Natural therapy 42.50
Orthopedist 25.48 Manual physician 74.01
Gynecologist 26.06 Orthomanual physician 87.31
Internal medicine 26.54 Reflexologist, magnetizer,
Psychiatrist 44.57 hypnotizer, paranormal healer, etc. 30.00
Rehabilitation physician 24.54 Home help (per hour) 30.00
Urologist 25.47 Unpaid help from family, friends (per hour) 15.00
Cardiologist 23.63 Transportation
Physiotherapy Taxi (per km) 1.33
Regular 30.37 Own car (per km) 0.57
Manual therapy 58.61 Public transport (per kin) 0.19
Caesar/Mensendieck 33.38
Ultrasound 34.63
Hospitalization (per day) 536.00
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The costs of GP contacts (US $ 13.44/consultation), outpatient special­
ist contacts (ranging from US $11.07 to 20.89/consultation), contacts with 
a physiotherapist (ranging from US $14.23 to 27.46/consultation), hospi­
talizations (US $251.17/day), and home help (US $l4.06/h) were based on 
charges. A population weighted average of the charges paid by socially 
insured and privately insured patients was used. The costs of drugs were 
based on Dutch pharmacy prices. Costs of alternative health care (ranging 
from US $19.92 to 84.35/consullation) were based on the guidelines of the 
professional associations for alternative medicine.
Direct nonhealth care costs. Data on direct non health care costs related to 
FM were also collected using the weekly cost diary. Patients were asked to 
report the following: type of transportation, distance travelled, hours of 
unpaid help from family or friends, housekeeper expenses, out of pocket 
expenses for activities such as swimming, physical exercise, etc., and out 
of pocket expenses for equipment, aids, modifications to the home, cloth­
ing, etc.» necessary to participate in the program or for self-management. 
Costs of unpaid help by family or friends were valued using the shadow
»
price for professional help (US $7.03/hour). For the other direct nonhealth 
care costs, the prices reported by the patient in the weekly cost diary were 
used.
Indirect costs. To calculate indirect costs, patients were asked to report in 
the weekly cost diary how many days Lhey were absent from their paid 
employment and how many days they were unable to perform their usual 
daily activities.
The indirect cost calculation was based on the human capital approach, 
which estimates the value of potential production lost during the entire peri­
od of absenteeism using, for both sexes, the national average gross hourly 
wage of US $10.78. The human capital approach measures the full poten­
tial loss of production but is likely to overestimate the actual loss, because 
in reality missing workers may be replaced by others, or the absentee may 
make up the lost production once he or she returns to work. To calculate the 
actual production loss, it is more realistic to assume that losses occur only 
during the time needed to replace the sick worker, or to reorganize the pro­
duction process. This is called the friction time. In the sensitivity analysis 
we estimate the value of the production loss assuming that no production is 
lost after this friction time. An estimation of the length of the friction peri­
od in the Netherlands, as of our study period, was obtained from 
Koopmanschap, et alH, who developed the Friction Cost Approach and cal­
culated that 3 months was necesssary, on average, to fill vacancies.
Utilities. The effects are measured in terms of utilities. A utility is a single 
comprehensive outcome measure that reflects the value or preference that 
respondents assign to a particular health state. This value is expressed on a 
scale ranging from 1 (perfect health) to 0 (death) and takes into account 
both the positive treatment effects and the negative side effects. We elicit­
ed utilities from patients participating in the trial by means of the 
Maastricht Utility Measurement Questionnaire. The instrument is a slight­
ly adapted Dutch version of the McMaster UtiliLy Measurement 
Questionnaire9,10. It is administered as an interview. Utility measurement 
using this instrument consists of 2 parts: first, patients are asked to describe 
their own health state of the past 2 weeks. They are requested to rate their 
current functional level using a 5 point scale ( 1 = best level, 5 = worst level) 
for 6 domains: physical state and mobility, self-care, emotions» leisure 
activities, pain and other complaints, and side effects of treatment. Second, 
patients are asked to value both an hypothetical reference state and their 
own health state by means of rating scale and standard gamble techniques. 
The hypothetical reference state is a description of a state with medium 
impaired quality of life, described in terms of the above 6 domains. This 
state serves as a reference point when patients value their own health state. 
The rating scale is visualized as a thermometer, with perfect health (100) 
and death (0) on the extremes. By means of the rating scale, utilities are 
measured directly by asking the patients to place the health states on the 
thermometer. By means of the standard gamble method, utilities are 
derived from the patients’ responses to decision situations under risk. In the 
standard gamble, patients are offered a choice between 2 alternatives: alter­
native A is a gamble with chance P of gaining perfect health and chance 1-P 
of dying immediately. Alternative B is the certainty of living in the health 
state being evaluated (either the patient’s own current health state or the ref­
erence state) for the remainder of one’s life. Probability P is varied in steps 
of 10% until the patient is indifferent between the 2 alternatives. According 
to the axioms of expected utility theory, the value of P at the indifference 
point is the expected value of this gamble, and thus the utility assigned to 
the health state being evaluated11. To facilitate the standard gamble ques­
tions, a chance board with a probability wheel was used as a visual aid.
Quality adjusted life years. The quality adjusted life years (QALY) is an 
effect measure that includes both the effects in terms of quality of life and 
effects in terms of survival12. To calculate QALY, utilities are used as cor­
rection factors to adjust years of life to allow for differences in the quality 
of life. For example, if the quality of life of a patient with a remaining life 
expectancy of 20 years improves by 0,5 of a utility because of a treatment, 
then this treatment results in 10 (20 x 0.5) QALY gained. QALY can be 
related to costs, resulting in a cost per QALY gained ratio. This ratio makes 
it possible to compare the cost effectiveness of the current intervention with 
other programs of all kinds. For our study the QALY gained by the ECO 
and EDI interventions will be calculated for illustrative reasons only.
Statistical analysis. To analyze the differences in direct, indirect, and total 
costs between the ECO and the EDI groups, costs per patient-year were cal­
culated13. This means that the observed costs of the patients with one or 
more missing weekly cost diaries were extrapolated to a one year period. 
Since the distribution of costs was skewed to the right, the nonparametric 
Mann-Whitney test was used to assess the statistical significance of cost 
differences between the ECO and EDI groups. Analyses of variance on log 
transformed costs per patient-year confirmed the results of the Mann- 
Whitney test; the p values of both tests were virtually the same.
The differences in the changes in utilities for the ECO, EDI, and WLC 
groups were analyzed using covariance analysis (ANCOVA), with the 
treatment group used as a factor and the baseline scores and a measure of 
social desirability as covariates.
RESULTS
Patient characteristics. One hundred thirty-one patients 
with FM were randomly assigned to one of the 3 different
groups. There were no statistical differences between the 
groups in clinical and sociodemographic characteristics14. 
Most patients were women (88%) with a mean age of 44 
years and pain duration of 10 years14. At baseline, the 
patients were asked if they had had contact with an outpa­
tient specialist or a physiotherapist or had had alternative 
health care contacts in the last 12 months .There was no dif­
ference in health care utilization among the groups in the 
year before the trial. Of the whole sample, 98% had at least 
one outpatient specialist contact, 72% had used physiother­
apy at least once, and 30% had at least one alternative health 
care contact in that year. Utilities did not differ between 
groups at baseline. The values (divided by 100) were ECO
0.46 (SD 0.12), EDI 0.45 (SD 0.15), WLC 0.47 (SD 0.13) 
for rating scale utilities and ECO 0.83 (SD 0.15), EDI 0.80 
(SD 0.18), WLC 0.78 (SD 0.16) for standard gamble utili­
ties. On the 6 domains of health, the average scores for all 
patients were 3.1 (SD 0.67) on physical state and mobility, 
1.9 (SD 0.71) on self care, 3.2 (SD 0,73) on emotions, 3.3 
(SD 0.64) on leisure activities, 3.9 (SD 0.60) on pain and 
other complaints, and 1.6 (SD 0.75) on side effects from 
treatment, The classification of the domains of health did
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not differ between the groups except for the domain “phys­
ical state and mobility.” For this domain there was a differ­
ence between the ECO and the EDI groups, the latter report­
ing a more favorable health state (p = 0.035).
Twenty-six patients did not complete the treatment to fol- 
lowup at one year (for ECO and EDI patients) or 6 weeks 
(for WLC patients). As reported14, there were no differences 
in demographic and clinical baseline characteristics between 
the dropouts and those who completed the study. The 
dropouts were included in the analyses until the moment of 
dropout.
Costs. Program costs. Using the standard therapy protocols, 
the costs of the ECO and EDI programs were estimated to 
be US $980 per patient (Table 2). Although the ECO pro­
gram is more demanding, since the program component 
given by the psychologist requires more active participation 
from the patient, there is no difference in costs between the
2 programs because the number of therapy hours given by 
the various therapists are equal.
Other direct health care costs. As noted, the other direct 
costs have been measured by means of the patients’ weekly 
cost diaries. During the entire followup period, patients in 
the ECO and EDI groups completed and returned 84 and 
80%, respectively, of the weekly cost diaries. Table 3 shows 
the annual volumes per patient for the various categories of 
health care use. Although not all categories show significant 
differences between the 2 groups, there is a clear pattern in 
the direction of the differences. All categories reflect higher 
health care use in the ECO group compared to the EDI 
group. It can also be seen that many of the patients in both 
groups received physiotherapy and called on unpaid help. 
Of the patients in the ECO and EDI groups, 49 and 36%, 
respectively, received physiotherapy at least once, and 29 
and 13%, respectively, received physiotherapy once or more 
than once per week during the entire year. Sixty percent and 
52% of patients in the ECO and EDI groups, respectively, 
received unpaid help from family or friends.
The mean total direct costs per patient-year, including
Table 2. Program costs of the ECO and EDI treatments per patient (US dollars).
Program Components No. of 30 Cost of 30 No. of Patients Total Cost/Patient
min Therapy min Therapy in Group
Sessions
Rehabilitation specialist (group therapy) 
Rehabilitation specialist
8 57.51 6 76.68
(individual therapy) 2 57.51 1 115.02
Welfare work 4 43.05 6 28.70
Psychology 36 50.81 6 304.86
Physiotherapy 12 16.42 6 32.85
Sports and games 14 19.50 6 45.50
Treatment program manager 6 16.42 6 16.42
Ergotherapy 7 25.07 6 29.25
Rehabilitation day treatment (days) 
Total program costs
12 27.56 1 330.76
980.04
Table 3. Mean (SD) health care use and mean (SD) use of other health care services per patient-year by cost cat­







General practitioner contacts 6.7 (7.2) 5.6 (7.2) 0.131
Outpatient specialist care contacts 6.9 (8.1 ) 3.3 (4.0) 0.121
Physiotherapy contacts 25.1 (30.4) 11.1 (20.3) 0,037
Alternative health care contacts 4.6(12.6) 1.3 (4.4) 0,025
Hospitalizations 1.8 (8.87) 0.5 (2.8) 0.376
Different medicines prescribed 6.0 (5.3) 5.7 (9.6) 0.162
Different OTC medications bought 9.2(17.2) 1.3 (2.9) 0.179
Hours of professional home help 20.6 (70.1 ) 17.9 (68 .8) 0.579
Hours of paid housekeeping help 76.5 (105.5) 34.8 (56.8) 0.137
Hours of unpaid help from family or friends 165.8 (267.8) 84.6 (133.0) 0.324
Health activities 55.8 (37.4) 48.1 (34.8) 0.275
Expenses for equipment, clothing, etc. 0.9 (1.4) 0.3 (0.8) 0.012
* Mann-Whitney test, OTC: over the counter medications.
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Figure 1. Estimated total costs per patient-year per treatment program (US dollars).
program costs, were estimated to be US $4260 (SD 6510) 
for the ECO group and US $2637 (SD 4649) in the EDI 
group. Figure 1 shows that both the direct health care costs 
(p = 0.003), the direct nonhealth care costs (p = 0.028), and 
the total direct costs (p = 0.001) per patient-year were sig­
nificantly lower in the EDI group than in the ECO group.
Table 4 shows the various components of direct costs 
measured by the patient-year approach. Although not all dif­
ferences in the subcategories of direct costs reach conven­
tional levels of statistical significance, direct costs were 
higher in the ECO group than in the EDI group in all cate­
gories. The differences in the costs for alternative health 
care, travel expenses, and expenses for equipment, clothing
etc,, reach statistical significance. The cumulative distribu­
tion of direct costs per patient over time shows that the costs 
in the ECO group increase faster than in the EDI group over 
the entire period.
Indirect costs. Patients in the ECO group reported a mean of 
42 (SD 82) days of pain related absence from work and a 
mean of 50 (SD 56) days on which they were not able to per­
form their usual daily activities. The EDI group reported 34 
(SD 71) and 44 (SD 55) days of absenteeism and inactivity, 
respectively. However, the differences between the 2 groups 
were not statistically significant on either measure. 
Consequently, although the estimated indirect costs based 
on the Human Capital Approach were also somewhat high-
Table 4. Mean (SD) direct costs per patient-year by cost category and treatment group (US dollars).
Cost Category ECO EDI p*
(n = 35) (n - 31 )
Health care costs
General practitioner 90 (206) 75 (311) 0.131
Outpatient specialist care 114 (351) 55 (151) 0.133
Physiotherapy 373 (1135) 154 (609) 0.083
Alternative health care 145 (905) 19(126) 0.023
Hospitalizations 330 (3327) 127 (1502) 0.376
Prescribed medications 119 (296) 63 (170) 0.071
OTC medications 35 (160) 5 (27) 0.218
Non-health care costs
Home help 289 (2104) 252 (2036) 0.579
Paid housekeeping help 353 (1165) 191 (700) 0.279
Unpaid help from family or friends 1165 (4016) 595 (1995) 0.324
Expenses for health activities 65 (203) 51 (190) 0.491
Travel expenses 92 (296) 52 (78) 0.047
Expenses for equipment, clothing, etc. 110 (639) 55 (111) 0.017
* Mann-Whitney test. OTC: over the counter medications.
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er for the ECO group (US $6379, SD 15,569) than the EDI 
group (US $5817, SD 14,303), they were not significantly 
different (p = 0.872).
Sensitivity analysis of the cost calculations. The analysis of 
the costs is based on several assumptions. The effect on the 
results of changing these assumptions can be assessed in a 
sensitivity analysis. A number of alternatives to the cost cal­
culations presented in the previous section are discussed 
below.
Including or excluding the group discussion component. 
The estimated program costs of US $980 per patient were 
based on a detailed cost accounting study, which showed 
these costs to be equal for the ECO and EDI programs. It 
could be argued that the presence of a psychologist during 
group discussion therapy (which is expensive) is not neces­
sary, and that someone with training in leading groups could 
also lead the sessions. The EDI program costs would then 
probably be lower. However, the group discussion compo­
nent in the EDI program was initially intended only as an 
attention control for possible aspecific effects of the cogni­
tive treatment. Cancelling this entire component reduces the 
costs of the EDI program by US $305 per patient.
Cost accounting versus charges. Another assumption was 
that the program costs were best estimated by an institution­
al cost accounting study. However, from the rehabilitation 
center’s perspective, costs are better reflected by charges. 
Based on the charge for outpatient rehabilitation care, US 
$106 per day, the program costs would be 12 x US $106 = 
US $1272 per patient. This is US $292 more per patient than 
was calculated initially. Because there is only one charge for 
outpatient rehabilitation care, irrespective of its content, 
there is again no difference between the costs of the ECO 
and EDI programs, whether the cognitive component is 
included or not.
Excluding high cost events. The difference in direct health 
care costs between the ECO and EDI programs was heavily 
influenced by differences in the costs associated with phys­
iotherapy, unpaid help, and hospitalizations. In the ECO 
group, 29% of patients had physiotherapy on average once 
or more than once per week for the entire year, compared to 
13% in the EDI group. Excluding the costs of physiothera­
py decreases the difference in direct health care costs from 
US $707 to US $561, still in favor of EDI. Excluding the 
costs of unpaid help for the patients with more than 10 hours 
of unpaid help a week ( 11 % in ECO and 3 % in EDI) reduces 
the difference in direct nonhealth care costs from US $916 
to 522, again in favor of the EDI program. The differences 
in hospitalization costs are due to there being 3 hospitalized 
patients in the ECO group in comparison with one hospital­
ized patient in the EDI group. Excluding the hospitalization 
costs reduces the difference in direct health care costs from 
US $707 to 504, still in favor of EDI. Even if all 3 high cost 
components are excluded, the difference in total direct
health care costs between the 2 groups is still significant.
Mean costs versus median costs. The calculations of total 
direct costs associated with both programs were based on 
the assumption that the costs are best estimated using mean 
costs. Estimating the incremental costs using median costs 
affects the cost differences between the 2 programs. The 
direct cost per patient of the ECO treatment is then US $421 
higher than for the EDI program.
Human capital approach versus friction cost approach, 
Using the main assumptions of the friction cost approach, 
instead of the human capital approach, reduced the indirect 
costs in both groups. During the whole research period 11 
patients were absent from paid employment or unable to 
perform housekeeping functions for more than 3 months. 
But because the number of patients who were absent for 
longer periods was comparable in both groups the friction 
cost approach does not change the finding that indirect costs 
are not significantly different between the EDI and the ECO 
group.
Overall, no matter what changes in cost assumptions 
were made, the cost differences between the ECO group and 
the EDI group were always in favor of the EDI group. This 
means that the sensitivity analyses strongly support the 
results found in the baseline analysis.
Utilities. The results of the clinical effect measures are 
described in detail elsewhere14. In the first part of the 
Maastricht Utility Measurement Questionnaire the patients 
had to classify themselves on 6 domains of health. In gener­
al, there was no change over time and no difference between 
the groups on these domains, except for significant differ­
ences during the treatment in the domain “leisure activities” 
in favor of the ECO condition compared to WLC (p = 
0.039), and in the domain of “self-care” in favor of EDI 
compared to WLC.
As for the utilities after 6 weeks of treatment, there was 
a significant difference in rating scale utilities between the 3 
groups (p = 0.037) (Table 5). This difference was due to a 
statistically significant greater improvement in the EDI 
group compared to the WLC group (p = 0.012).
Figure 2 shows greater improvement in rating scale util­
ities in the EDI group at the POST measurement (EDI 0.108 
vs ECO 0.070; p = 0.304) and FU1 (EDI 0.107 vs ECO 
0.057; p = 0.338), though this trend is not significant. At 
FU2 the improvement is greater in the ECO group (ECO 
0.093 vs EDI 0.067; p = 0.590). Again, this difference is not
significant. The change in standard gamble utilities was not 
significantly different at either POST, FU1, or FU2.
QALY. The changes in rating scale utilities and standard 
gamble utilities from baseline at measurement were used to 
calculate the QALY gained by the alternative programs. 
Based on rating scale results, Figure 2 shows that the EDI 
treatment produced a gain of 0.027 QALY per patient per
«
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Table 5, Differences in changes in utilities after 6 weeks between ECO, EDI, and WLC groups.
ECO EDI WLC p*
(n = 32) It
£ m<1
Rating scale**, Mean (SDf) +0.070 (0.J3) +0.108 (0.13) +0.018 (0.13) 0.037
SLandard gamble, Mean (SD) +0.003 (0.12) +0.005 (0.12) -0.028 (0.12) 0.473
* From ANCOVA: utilities are adjusted for baseline and social desirability.
** Rating scale utilities were divided by 100.
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Figure 2. Change in rating scale utilities, adjusted for baseline differences and social desirability, Rating scale 
utilities were divided by 100.
year compared to the ECO treatment. Standard gamble util­
ity measurements showed that the EDI treatment yielded a 
gain of 0.022 QALY compared to the ECO treatment. 
Because these figures combine the results from different 
numbers of patients at different moments, the statistical sig­
nificance of this gain could not be tested. However, the dif­
ferences when the patients who did not complete the entire 
year to FU2 were excluded were not significant (p = 0.245 
and p = 0.220 for changes in rating scale and standard gam­
ble utilities, respectively).
DISCUSSION
This economic evaluation study showed that the interven­
tion combining group education and group discussion (EDI) 
is preferred over the intervention that combined group edu­
cation and group cognitive therapy (ECO), because the pro** 
gram costs of both interventions were equivalent, but both 
the direct health care and nonhealth care costs were signifi­
cantly lower for patients participating in the EDI program.
All subcategories of direct costs differed in the same direc­
tion as the total costs, though not all these differences 
reached statistical significance. This is also true for the indi­
rect costs. The cost differentials found are robust through a 
range of plausible values used in sensitivity analysis.
Despite the lower costs of the EDI program, no signifi­
cant differences in utilities were found, except for the sig­
nificantly greater improvement in rating scale utilities in the 
EDI group compared to the WLC group at the posttreatment 
measurement. At best, the rating scale utilities suggest a 
short term trend toward greater improvement in quality of 
life in the EDI group compared to the ECO group, a trend 
that seems to disappear in the long run. Overall, using the 
rating scale method to measure utilities, this results in a non­
significant estimate of 0.027 QALY gained due to the EDI 
program. Such a small increase in QALY indicates that the 
EDI program has little advantage over the ECO program, 
except that it is less costly.
The observation that direct medical and nonmedical costs
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were lower for the EDI program than the ECO program is 
not in accordance with pretrial expectations* The overall 
goal of the cognitive component of the ECO program was to 
increase patients’ pain control using techniques such as 
diverting attention, reinterpreting pain sensations, coping 
self-statements, etc. As a result, health care resource use was 
expected to be lower rather than higher in the ECO group 
compared to the EDI group. One possible explanation may 
be that cognitive group therapy increases the patient’s 
awareness of the illness and the problems and weaknesses 
associated with it. This, in turn, may have increased the 
demand for both professional and paraprofessional help. A 
broader and more intense cognitive program that also 
addresses individual patients’ needs might have prevented 
the increase in health care use. Another explanation would 
be that the group discussion component of the EDI program, 
which was intended only as an attention placebo, may have 
given the patients support and understanding. This resulted 
in less demand for help in the EDI group from professional 
care givers, family members, or friends, compared to the 
ECO group. In that case, the group discussions can no 
longer be seen as a placebo but rather as an active, though 
not very effective, treatment.
Of note, because we did not measure health care resource 
use in the year preceding the trial, it can be questioned 
whether there was a difference in health care resource use 
between the groups at baseline. We have several arguments 
that this was not the case. First, there was no difference in 
clinical characteristics between the groups. In addition, 
there was no difference between the groups’ proportionate 
use of outpatient specialist care, physiotherapy, and alterna­
tive health care contacts in the last 12 months. Although we 
had no information about the frequency or content of the 
contacts, we have no reason to believe that health care use 
was different between the groups before the trial.
Previous FM studies involving costs have been restricted 
to calculations of changes in health care resource use. In our 
study, efforts were made to take into account all relevant 
categories of costs, including the nonmedical costs borne by 
patients and their families. Because of the patients’ role in 
reporting, the identification and measurement of these non­
medical costs is somewhat arbitrary. However, in the sensi­
tivity analysis we have shown that different assumptions 
regarding these costs or even excluding these costs would 
not have altered the overall conclusion.
Adding utility measures to the battery of pain specific 
and domain specific outcome measures described in Part I14 
allowed us to assess whether the changes in these outcome 
measures have any effect on the patient’s valuation of his or 
her overall health state. Utilities are meant to express the net 
effect of the treatment programs, because both the positive 
and negative effects of the programs are integrated in the 
overall value a patient assigns to his health state. However, 
the large difference between the rating scale and standard
gamble methods reflects the methodological problems 
underlying utility measurement. Numerous publications, 
some using the same instrument we did, have reported that 
rating scale values are lower than standard gamble val­
ues15-20. We found differences of between 25 and 35%, 
depending on the moment of measurement. Several phe­
nomena might explain this difference, the most important 
being a patient’s risk attitude, which plays a role in the stan­
dard gamble technique but not in the rating scale technique. 
Risk-averse behavior is probably reinforced in this study 
because our patients with FM have tried numerous and usu­
ally not very effective treatments before. This might have 
caused a reluctance to try a new (although hypothetical) 
treatment that gives them chance P to gain perfect health. 
Furthermore, in our study as in other studies, P was varied 
in steps of 10%1CU7,19. For patients with FM these steps are 
probably too large. In the first step, patients have either to 
claim that they are in full health or accept a therapy with a 
10% risk of dying; more than 40% of the patients were not 
prepared to take this risk on at least one measurement. Thus, 
these large steps produce an upward bias in the standard 
gamble utilities. Smaller changes might have produced a 
greater variance in utilities. Due to this large ceiling effect, 
the standard gamble utilities were already so high at base­
line that there was little likelihood of recording an improve­
ment. Therefore, it appears justified to conclude that the 
standard gamble measurement protocol used here is not suit­
able for eliciting utilities from certain types of chronic 
patients, such as those with FM.
For decision making purposes, with regard to the wide 
adoption of the programs, both the ECO and EDI programs 
should have been compared to the usual care alternative. 
However, considering the enormous variety of treatments 
for FM, it was not possible to define an average form of 
medical management. Evaluating the available treatments 
would require extra studies. “Usual care’5 also could not be 
derived from the health care use pattern of patients on the 
waiting list, because patients stayed on this list for only a 
relatively short time and are likely to receive minimal or no 
care in anticipation of future treatment. Furthermore, the 
treatment given patients in the rehabilitation center does not 
represent “usual care” for FM in the Netherlands. As a con­
sequence it was not possible to calculate the incremental 
cost effectiveness ratios of the ECO and EDI programs com­
pared to usual care.
In summary, we found that the addition of a group dis­
cussion component to an educational program was more 
cost effective than the addition of a cognitive component. 
The first led to considerable savings compared to the latter 
in both direct medical and nonmedical costs, whereas the 
clinical outcome measures showed no clear differences 
between the 2 groups. From a cost-utility perspective, the 
EDI program is preferable to the ECO program. Because 
neither intervention produced significant improvements in
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quality of life, the search for effective therapy for FM must 
go on.
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